All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Antiretroviral therapy (ART) has dramatically improved the overall survival of people living with human immunodeficiency virus (HIV), but the life-long tolerability of ART has yet to be revealed. Raltegravir (Isentress, Merck & Co., Inc., Kenilworth, NJ, USA) is the world's first in class of HIV integrase strand transfer inhibitor (INSTI) for the treatment of HIV-1 infection. The safety and efficacy of raltegravir administration in clinical trials for up to 5 years among HIV-infected patients in North American, South American, Australian, and South Asian countries have been previously reported \[[@pone.0210384.ref001]--[@pone.0210384.ref008]\]. After its approval in 2007 in the United States, 112 other countries also approved raltegravir \[[@pone.0210384.ref009]\]. In Japan, use of a 400-mg raltegravir tablet twice daily was approved by the regulatory authority in June 2008, and this drug has been marketed in Japan since July 2008. However, the safety and efficacy of raltegravir has not been evaluated in clinical trials specifically targeting Japanese patients.

In Japan, around 1,500 HIV/Acquired immunodeficiency syndrome (AIDS) cases have been reported annually since 2007 and 1,448 HIV/AIDS (1,380 males) cases were reported in 2016. Men who have sex with men (MSM), including bisexual contacts, made up 73% (735/1,011) of all HIV cases and the majority was in their 20's to 40's. The cumulative number of reported HIV/AIDS cases (excluding coagulating agent-related cases) was 27,443 as of the end of 2016 \[[@pone.0210384.ref010]\].

A rapid drug approval process is applied for antiretroviral agents in Japan, and this approval is based on non-clinical and clinical data reported from overseas as an orphan drug. As such, raltegravir was approved for clinical use under the condition of conducting a post-marketing surveillance to collect domestic data on the safety and effectiveness of this agent in clinical practice. Because antiretroviral agents are usually used concomitantly with other anti-HIV drugs, all pharmaceutical companies with an approved anti-HIV drug work together to conduct a HIV-related drug (HRD) cooperative survey \[[@pone.0210384.ref011]\].

The surveillance of raltegravir through the HRD cooperative survey started at the time of its marketing, in July 2008. To date, no data on the long-term tolerability and effectiveness in Japan of either raltegravir or other INSTI agents are available. Furthermore, only a few studies on the long-term effectiveness of key drug have been conducted in other countries; they include the 12-year experience of nevirapine use in France \[[@pone.0210384.ref012]\], a 9-year cohort of efavirenz and nevirapine in Senegal \[[@pone.0210384.ref013]\], a 10-year cohort on efavirenz and nevirapine in Uganda \[[@pone.0210384.ref014]\], and the 7-year efficacy of a lopinavir/ritonavir-based regimen in the United States \[[@pone.0210384.ref015]\]. Therefore, the objective of the present study was to assess the long-term tolerability and effectiveness of raltegravir in Japanese clinical practice, using the HRD cooperative survey data collected as post-marketing surveillance over the approximately 9 years from 2008 to 2017.

Methods {#sec002}
=======

Study design {#sec003}
------------

This observational survey used post-marketing surveillance data collected for the HRD cooperative survey and was conducted in accordance with the requirements of the pharmaceutical affairs law and the ministerial ordinance of 'Good Post-Marketing Study Practice (GPSP)'. At their discretion, investigators of the contracted institutions registered patients who were newly prescribed with particular antiretroviral agents and provided data on the safety and effectiveness of the antiretroviral agents for each treated patient. Patient background information, such as age, sex, comorbidity on administration (including hepatic disease and renal disease), presence of allergy, status of anti-HIV drug use, and concomitant drug use (dose level, dosing period), was collected at registration. Data were collected by filling out a case report form upon registration and annually thereafter. If a patient experienced an adverse event (AE), the corresponding data were reported immediately using the AE report form. The management of the HRD cooperative survey was delegated to CMIC PMS Co., Ltd. (Tokyo, Japan). All data were fully anonymized before the authors of this study accessed them.

Study population {#sec004}
----------------

Data on patients registered as newly treated with raltegravir between July 2008 (the beginning of raltegravir marketing) and March 2017 were drawn from the HRD cooperative survey for this study. Of the 33 institutions in which patients were prescribed raltegravir, three institutions did not agree to the disclosure of information, so they were excluded from these analyses.

Ethics statement {#sec005}
----------------

This post-marketing surveillance (PMS) conducted in accordance with Good Post-marketing Study Practice for drugs \[GPSP; Ministry of Health, Labour, and Welfare (MHLW) ministerial ordinance\]. The survey protocol was reviewed and approved in advance by the Pharmaceuticals and Medical Devices Agency (PMDA). The requirements of ethical approval by an institutional review board and informed consent from individual patients for this survey were waived. However, all 30 facilities obtained approval in advance by their institutional review board according to each institutional rule. Names of the 30 facilities were anonymized for publication due to the contract of HRD cooperative survey. Of these 30 facilities, 29 are HIV specialized hospitals, 22 are national or public hospitals, and mean number of beds are 758 (range 135--1,379).

Safety assessments {#sec006}
------------------

To assess the safety of raltegravir, AEs and abnormal variations in laboratory test parameters (i.e. haematology test, clinical biochemical test, urine analysis, and ocular abnormalities) were collected during the treatment period. All events with a relationship between the AE and drug were defined as adverse drug reactions (ADRs). AEs and ADRs were classified according to the Medical Dictionary for Regulatory Activities/Japanese version (MedDRA/J Ver.20.0).

Effectiveness assessments {#sec007}
-------------------------

For the assessment of effectiveness, the CD4^+^ cell counts, HIV-1 RNA levels, and HIV infection clinical stages (i.e. Centers for Disease Control and Prevention \[CDC\] categories \[[@pone.0210384.ref016]\]) before and after raltegravir administration (baseline and treatment period) were collected. Infection clinical stages were classified as follows: category A was defined as asymptomatic HIV infection, category B was defined as symptomatic HIV infection, and category C was defined as acquired immunodeficiency syndrome (AIDS).

Statistical analysis {#sec008}
--------------------

Patient demographics, clinical characteristics, AEs, and ADRs were summarized descriptively from the collected data. The long-term safety of raltegravir was assessed by summarizing the risk of ADRs by the time of occurrence from the start of raltegravir treatment: \<90 days, between 90 and \<180 days, between 180 and \<270 days, between 270 days and \<1 year, between 1 year and \<2 years, between 2 and \<3 years, between 3 and \<4 years, between 4 and \<5 years, between 5 and \<6 years, and ≥6 years. To assess potential risk factors for ADRs, the ADR occurrence was further analysed according to baseline characteristics using a Fisher's exact test or Cochran-Armitage test. Changes in the median HIV-1 RNA levels and median CD4^+^ cell counts were calculated over time at 0, 3, 6, 12, 24, 36, 48, 60, 72, 84, and 96 months after the start of raltegravir treatment for treatment-naïve patients and treatment-experienced patients. The proportion of patients with \<50 copies/mL of HIV-1 RNA, including blip cases (i.e. patients with \<50 copies/mL of HIV-1 RNA with transient increases up to 1,000 copies/mL), was also calculated for the virologic assessment, and its 95% confidential intervals was estimated using Clopper-Pearson method. All statistical tests were two-sided at a significance level of 0.05 and were conducted using SAS Release 9.4 (SAS Institute, Inc., Cary, NC, USA).

Results {#sec009}
=======

Patient disposition {#sec010}
-------------------

A total of 1,303 patients were prescribed with raltegravir across 30 institutions of the HRD cooperative survey. Of these, 10 patients were excluded due to the fact that their prescription of raltegravir was written before its launch in Japan. 1,293 patients were included for the safety analysis. For the analysis of raltegravir effectiveness, one patient with an off-label use of raltegravir and 115 patients with no recorded CD4^+^ cell counts, number of HIV-1 RNA copies, or CDC categories either before or after raltegravir administration were excluded. Finally, data from the remaining 1,178 patients were included for the effectiveness analysis ([Fig 1](#pone.0210384.g001){ref-type="fig"}).

![Patient disposition.\
CRF: case report form, CDC: Centers for Disease Control and Prevention.](pone.0210384.g001){#pone.0210384.g001}

Patient demographics and clinical characteristics {#sec011}
-------------------------------------------------

The patient demographics and clinical characteristics at baseline are summarized in [Table 1](#pone.0210384.t001){ref-type="table"}. In the safety analysis set (n = 1,293), 94.1% of patients were male, and the median age at baseline was 41 years (Interquartile range, IQR: 34--50 years). The majority of patients belonged to pre-treatment CDC category A (54.5%), followed by categories C (30.9%) and B (6.0%). The prevalence of comorbidity was 68.5%. Hepatic disease and renal disease were present at baseline in 25.1% and 4.9% of the patients, respectively. Comorbidities that were reported in \>50 patients at baseline were: pneumocystis jirovecii pneumonia (n = 122; 9.4%), hypertension (n = 99; 7.7%), hyperlipidaemia (n = 68; 5.3%), insomnia (n = 66; 5.1%), diabetes mellitus (n = 55; 4.3%), and hyperuricaemia (n = 50; 3.9%). Most patients (99.1%) were prescribed with a dose of 800 mg of raltegravir per day. The median treatment period from the start of raltegravir administration was 1,123 days, and 84.2% of the patients had been treated with raltegravir longer than 1 year.

10.1371/journal.pone.0210384.t001

###### Patient baseline characteristics.

![](pone.0210384.t001){#pone.0210384.t001g}

  Characteristics                                                                                                  Total                 
  ---------------------------------------------------------------------------------------------------------------- --------------------- --------
  Age (Years) median                                                                                               41.00 (IQR: 34--50)   
   ≤14 years                                                                                                       0                     (0.0)
   15‒\<65 years                                                                                                   1,218                 (94.2)
   ≥65 years                                                                                                       75                    (5.8)
  Sex                                                                                                                                    
   Male                                                                                                            1,217                 (94.1)
  Clinical status of HIV infection                                                                                                       
  (CDC category) prior to raltegravir administration for patients aged ≥15[^a^](#t001fn001){ref-type="table-fn"}                         
   A                                                                                                               705                   (54.5)
   B                                                                                                               77                    (6.0)
   C                                                                                                               399                   (30.9)
   Unknown/not stated                                                                                              112                   (8.7)
  Comorbidity, present                                                                                             886                   (68.5)
  Hepatic disease [^b^](#t001fn002){ref-type="table-fn"}, present                                                  325                   (25.1)
   Hepatitis A                                                                                                     3                     (0.2)
   Hepatitis B                                                                                                     130                   (10.1)
   Hepatitis C                                                                                                     115                   (8.9)
   Others                                                                                                          64                    (4.9)
  Renal disease [^c^](#t001fn003){ref-type="table-fn"}, present                                                    63                    (4.9)
  Treatment period with raltegravir                                                                                                      
   \<90 days                                                                                                       63                    (4.9)
   90‒\<180 days                                                                                                   40                    (3.1)
   180‒\<270 days                                                                                                  56                    (4.3)
   270‒\<1 year                                                                                                    43                    (3.3)
   1‒\<2 years                                                                                                     196                   (15.2)
   2‒\<3 years                                                                                                     229                   (17.7)
   3‒\<4 years                                                                                                     248                   (19.2)
   4‒\<5 years                                                                                                     199                   (15.4)
   5‒\<6 years                                                                                                     141                   (10.9)
   ≥6 years                                                                                                        76                    (5.9)

^a^CDC category A was defined as asymptomatic HIV infection, category B was defined as symptomatic HIV infection, and category C was defined as acquired immunodeficiency syndrome (AIDS).

^b^Hepatic disease was defined if checkbox with "Hepatitis A, B, C, or other hepatic disorders" was selected as present, or hepatic related disease \[Preferred Term (PT)/Lowest Level Terms (LLT) linked Standarized MedDRA Queries (SMQ) of "Hepatic disorders"\] was reported in other comorbidity column.

^c^Renal disease was defined if checkbox with "Renal disorders" was selected as present, or renal related disease \[primary System Organ Class (SOC) of "Renal and urinary disorders" and PT/LLT linked SMQ of "Acute renal failure" or "Renovascular disorders"\] was reported in other comorbidity column.

Note: Data are presented as frequencies and percentages unless otherwise indicated. Due to rounding, some percentages may not sum up to 100%.

Safety analysis {#sec012}
---------------

### Adverse drug reactions and laboratory abnormalities {#sec013}

Of 1,293 patients in the safety analysis population, 346 ADRs were reported in 223 patients, with an overall risk rate of 17.25%. Of those, 55 serious ADRs were reported in 31 patients (2.40%). The most common ADRs were abnormal hepatic function (17 events; 1.31%), hyperlipidaemia (14 events; 1.08%), renal impairment (11 events; 0.85%), hyperuricaemia (11 events; 0.85%), liver disorder (11 events; 0.85%), dyslipidaemia (9 events; 0.70%), hypertension (9 events; 0.70%), hypertriglyceridaemia (8 events; 0.62%), immune reconstitution inflammatory syndrome (8 events; 0.62%), insomnia (7 events; 0.54%), and increased blood creatinine levels (7 events; 0.54%) ([Table 2](#pone.0210384.t002){ref-type="table"}).

10.1371/journal.pone.0210384.t002

###### Adverse drug reactions and laboratory abnormalities reported in patients with ≥ 5 events (n = 1,293).

![](pone.0210384.t002){#pone.0210384.t002g}

  --------------------------------------------------------------------------------------------------------------------
  Adverse drug reactions\                                                                   Number of event   (%)
  (MedDRA system organ class and term)                                                                        
  ----------------------------------------------------------------------------------------- ----------------- --------
  Infections and infestations (n = 11, 0.85%)                                                                 

  Neoplasms benign, malignant and unspecified (including cysts and polyps) (n = 6, 0.46%)                     

  Blood and lymphatic system disorders (n = 6, 0.46%)                                                         

  Immune system disorders (n = 8, 0.62%)                                                                      

   Immune reconstitution inflammatory syndrome                                              8                 (0.62)

  Endocrine disorders (n = 1, 0.08%)                                                                          

  Metabolism and nutrition disorders (n = 53, 4.10%)                                                          

   Diabetes mellitus                                                                        5                 (0.39)

   Hypertriglyceridaemia                                                                    8                 (0.62)

   Hyperuricaemia                                                                           11                (0.85)

   Dyslipidaemia                                                                            9                 (0.70)

   Hyperlipidaemia                                                                          14                (1.08)

  Psychiatric disorders (n = 13, 1.01%)                                                                       

   Insomnia                                                                                 7                 (0.54)

  Nervous system disorders (n = 13, 1.01%)                                                                    

   Headache                                                                                 5                 (0.39)

  Eye disorders (n = 1, 0.08%)                                                                                

  Cardiac disorders (n = 6, 0.46%)                                                                            

  Vascular disorders (n = 11, 0.85%)                                                                          

   Hypertension                                                                             9                 (0.70)

  Respiratory, thoracic and mediastinal disorders (n = 4, 0.31%)                                              

  Gastrointestinal disorders (n = 25, 1.93%)                                                                  

  Hepatobiliary disorders (n = 36, 2.78%)                                                                     

   Hepatic function abnormal                                                                17                (1.31)

   Liver disorder                                                                           11                (0.85)

  Skin and subcutaneous tissue disorders (n = 19, 1.47%)                                                      

  Musculoskeletal and connective tissue disorders (n = 11, 0.85%)                                             

  Renal and urinary disorders (n = 19, 1.47%)                                                                 

   Renal impairment                                                                         11                (0.85)

  Reproductive system and breast disorders (n = 1, 0.08%)                                                     

  General disorders and administration site conditions (n = 8, 0.62%)                                         

  Investigations (n = 55, 4.25%)                                                                              

   Blood creatinine increased                                                               7                 (0.54)

   Gamma-glutamyltransferase increased                                                      5                 (0.39)

   Renal function test abnormal                                                             5                 (0.39)

  Injury, poisoning and procedural complications (n = 4, 0.31%)                                               
  --------------------------------------------------------------------------------------------------------------------

For predefined events of interest on monitoring the safety of raltegravir, the most frequently reported ADRs that were related to musculoskeletal and connective tissue disorders were back pain (3 events; 0.23%), followed by rhabdomyolysis (2 events; 0.15%) and osteoporosis (2 events; 0.15%) ([Table 2](#pone.0210384.t002){ref-type="table"}, [S1 Appendix](#pone.0210384.s001){ref-type="supplementary-material"}). As for skin and subcutaneous tissue disorders, pruritus (4 events; 0.31%) and rash (3 events; 0.23%) were reported. The reported cardiac disorder-related ADRs were cardiac failure (2 events; 0.15%) and atrial fibrillation, myocardial infarction, supraventricular extrasystoles, and ventricular extrasystoles (1 event each; 0.08%). Benign, malignant, and unspecified neoplasms were reported as ADRs in 6 cases (0.46%), including Kaposi's sarcoma (2 events; 0.15%), bladder cancer (1 event; 0.08%), skin papilloma (1 event; 0.08%), squamous cell carcinoma of the lung (1 event; 0.08%), and thymoma (1 event; 0.08%).

### Long-term safety {#sec014}

The ADR risk by the time period from raltegravir treatment initiation was 10.20% (20/196 cases), 16.16% (37/229 cases), 16.13% (40/248 cases), 22.11% (44/199 cases), 18.44% (26/141 cases), and 23.68% (18/76 cases) for treatment durations of between 1 and \<2 years, 2 and \<3 years, 3 and \<4 years, 4 and \<5 years, 5 and \<6 years, and ≥6 years, respectively ([Table 3](#pone.0210384.t003){ref-type="table"}). In particular, the risk of metabolism and nutrition disorders increased as the raltegravir treatment period lengthened: 1.02% (2/196 cases), 2.18% (5/229 cases), 4.44% (11/248 cases), 7.04% (14/199 cases), 7.09% (10/141 cases), and 10.53% (8/76 cases) after treatment periods of between 1 and \<2 years, 2 and \<3 years, 3 and \<4 years, 4 and \<5 years, 5 and \<6 years, and ≥6 years, respectively (Cochrane-Armitage test: *p* \< 0.001).

10.1371/journal.pone.0210384.t003

###### Risk of adverse drug reactions by time period from the start of raltegravir treatment.

![](pone.0210384.t003){#pone.0210384.t003g}

                             \<90 days   90‒\<180 days   180‒\<270 days   270 days‒\<1 year   1‒\<2 years   2‒\<3 years   3‒\<4 years   4‒\<5 years   5‒\<6 years   ≥6 years   unknown/not stated   Total
  -------------------------- ----------- --------------- ---------------- ------------------- ------------- ------------- ------------- ------------- ------------- ---------- -------------------- -------
  **Patients, n**            63          40              56               43                  196           229           248           199           141           76         2                    1,293
  **Patients with ADR, n**   17          8               9                3                   20            37            40            44            26            18         1                    223
  **ADR, event**             25          12              16               3                   25            56            65            70            42            30         2                    346
  **Patients with ADR,%**    26.98       20.00           16.07            6.98                10.20         16.16         16.13         22.11         18.44         23.68      50.00                17.25

ADR: adverse drug reactions

### Assessment of baseline factors affecting ADR development {#sec015}

ADR rates were significantly higher in patients with an older age (*p* = 0.039), CDC category of B (*p* = 0.019), the presence of any comorbidities (19.86%, *p* \< 0.001), the presence of hepatic disease (22.77%, *p* = 0.003), the presence of allergic disease (26.49%, *p* \< 0.001), or an increasing number of concomitant medications (*p* \< 0.001) ([Table 4](#pone.0210384.t004){ref-type="table"}).

10.1371/journal.pone.0210384.t004

###### Risk of adverse drug reactions according to baseline characteristics.
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  Patient characteristics                      n       Adverse drug reactions   p value[^a^](#t004fn001){ref-type="table-fn"}           
  -------------------------------------------- ------- ------------------------ ----------------------------------------------- ------- ---------
  **Total**                                    1,293   223                      346                                             17.2    \-
  **Sex**                                                                                                                               
   **Male**                                    1,217   209                      321                                             17.17   0.755
   **Female**                                  76      14                       25                                              18.42   
  **Age**                                                                                                                               
   **≤14 years**                               0       0                        0                                               \-      0.039
   **15‒\<25 years**                           48      6                        10                                              12.50   
   **25‒\<35 years**                           282     40                       57                                              14.18   
   **35‒\<45 years**                           473     83                       119                                             17.55   
   **45‒\<55 years**                           258     46                       72                                              17.83   
   **55‒\<65 years**                           157     33                       66                                              21.02   
   **65‒\<75 years**                           67      12                       17                                              17.91   
   **≥75 years**                               8       3                        5                                               37.50   
  **Pre-treatment CDC category (age ≥15)**                                                                                              
   **A**                                       705     106                      162                                             15.04   0.019
   **B**                                       77      18                       23                                              23.38   
   **C**                                       399     83                       138                                             20.80   
  **Presence of comorbidities**                                                                                                         
   **Present**                                 886     176                      284                                             19.86   \<0.001
   **Absent**                                  407     47                       62                                              11.55   
  **Renal disease comorbidities**                                                                                                       
   **Present**                                 63      14                       29                                              22.22   0.304
   **Absent**                                  1,230   209                      317                                             16.99   
  **Hepatic disease comorbidities**                                                                                                     
   **Present**                                 325     74                       118                                             22.77   0.003
   **Absent**                                  968     149                      228                                             15.39   
  **Presence of allergy**                                                                                                               
   **Present**                                 268     71                       107                                             26.49   \<0.001
   **Absent**                                  866     133                      209                                             15.36   
  **Duration of treatment with raltegravir**                                                                                            
   **\<90 days**                               63      17                       25                                              26.98   0.307
   **90‒\<180 days**                           40      8                        12                                              20.00   
   **180‒\<270 days**                          56      9                        16                                              16.07   
   **270‒\<1 year**                            43      3                        3                                               6.98    
   **1‒\<2 years**                             196     20                       25                                              10.20   
   **2‒\<3 years**                             229     37                       56                                              16.16   
   **3‒\<4 years**                             248     40                       65                                              16.13   
   **4‒\<5 years**                             199     44                       70                                              22.11   
   **5‒\<6 years**                             141     26                       42                                              18.44   
   **≥6 years**                                76      18                       30                                              23.68   
  **Concomitant medications**                                                                                                           
   **Yes**                                     1,292   223                      346                                             17.26   1.000
   **No**                                      1       0                        0                                               0.00    
  **Number of concomitant medications**                                                                                                 
   **1**                                       440     30                       36                                              6.82    \<0.001
   **2**                                       199     24                       32                                              12.06   
   **3**                                       136     18                       26                                              13.24   
   **4**                                       105     20                       22                                              19.05   
   **≥5**                                      412     131                      230                                             31.80   

^a^ *p*-values for Fisher's exact test or Cochran-Armitage test

ADR: adverse drug reactions

Analysis for effectiveness parameters {#sec016}
-------------------------------------

### Virologic responses {#sec017}

At the start of the treatment, the median HIV-1 RNA viral loads among the treatment-naïve patients were considerably higher compared with those of treatment-experienced patients (64,000 vs. 39 copies/mL), but this level rapidly decreased to 78.5 copies/mL after one month of raltegravir treatment. Median HIV-1 RNA viral loads in treatment-naïve and treatment-experienced groups each maintained below 40 copies/mL after three months of raltegravir treatment ([Fig 2](#pone.0210384.g002){ref-type="fig"}, [S2 Appendix](#pone.0210384.s002){ref-type="supplementary-material"}). Regarding long-term virologic suppression in both treatment-naïve and treatment-experienced patients, the proportion of patients with HIV-1 RNA viral loads of less than 50 copies/mL (including blip cases) was 81.79% (503/615 cases, 95%CI: 78.51--84.76) at 3 months and 89.47% (620/693, 86.94--91.65) at 6 months, and it exceeded 90% with 92.94% (724/779, 90.91--94.64), 93.70% (654/698, 91.63--95.38), 93.81% (515/549, 91.45--95.67), 93.30% (348/373, 90.26--95.62), 92.09% (198/215, 87.64--95.33), 91.01% (81/89, 83.05--96.04), and 92.00% (23/25, 73.97--99.02) at 12, 24, 36, 48, 60, 72, and 84 months, respectively. Although this proportion reached 100% (95%CI: 29.24--100.00) at 96 months, this group included only three treatment-experienced patients ([Fig 3](#pone.0210384.g003){ref-type="fig"}, [S3 Appendix](#pone.0210384.s003){ref-type="supplementary-material"}).

![Changes in the median HIV-1 RNA viral loads of treatment-naïve patients and treatment-experienced patients.\
The markers indicate the median.](pone.0210384.g002){#pone.0210384.g002}

![Proportion of patients with \<50 copies/mL of HIV-1 RNA in patients treated with raltegravir.\
Error bars indicate 95% confidence intervals.](pone.0210384.g003){#pone.0210384.g003}

### Immunologic responses {#sec018}

At the start of raltegravir treatment, the median CD4^+^ cell counts in treatment-naïve patients were lower compared with those in treatment-experienced patients (216 vs. 408 cells/μL), but the CD4^+^ cell counts in the treatment-naïve group reached 346 cells/μL after 3 months and 522 cells/μL after 36 months of raltegravir treatment ([Fig 4](#pone.0210384.g004){ref-type="fig"}, [S4 Appendix](#pone.0210384.s004){ref-type="supplementary-material"}). The CD4^+^ cell counts in both the treatment-naïve and treatment-experienced groups displayed an increasing trend throughout the treatment period; the CD4^+^ cell counts were maintained at over 500 cells/μL after 36 months in treatment-naïve patients and after 48 months in treatment-experienced patients.

![Change in median CD4+ cell counts of treatment-naïve patients and treatment-experienced patients.\
The markers indicate the median.](pone.0210384.g004){#pone.0210384.g004}

### CDC categories {#sec019}

Most of the patients assessed as belonging to category A (505/512 cases; 98.6%) and category B (51/53 cases; 96.2%) maintained their pre-treatment CDC category even after raltegravir administration. Only nine cases had disease progression.

Discussion {#sec020}
==========

This study was conducted using the results of a nine-year post-marketing surveillance on raltegravir in Japan. Data from 1,303 patients were initially extracted from the HRD cooperative survey, and, after excluding 10 ineligible patients, a total of 1,293 patients were included in the safety analysis. The overall ADR risk (17.25%) in this survey was fairly low, compared with previous international clinical trials reporting the ADR incidence for raltegravir, which ranged from approximately 44%‒61% with study periods spanning 1‒5 years \[[@pone.0210384.ref001]--[@pone.0210384.ref008]\]. Hyperlipidaemia and abnormal hepatic function were the most commonly reported ADRs in our study, with risks slightly exceeding 1%. No specific tendency was observed in the occurrence of other ADRs, including rash, cardiovascular disorders, elevated creatine kinase, and musculoskeletal and connective tissue disorders (i.e. rhabdomyolysis and myopathy) reported in previous clinical trials with a 2-year maximum of raltegravir administration \[[@pone.0210384.ref001],[@pone.0210384.ref002],[@pone.0210384.ref004],[@pone.0210384.ref017]\]. Muscle symptoms including myalgia, pain in extremity and rhabdomyolysis (0.31%, 4 cases) and CPK increase (0.15%, 2 cases) were fairly low in this survey, compared with other observational study (SCOLTA project) in patients receiving raltegravir, which were 5.2% and 21.1%, respectively \[[@pone.0210384.ref018]\]. SCOLTA project also investigated drug-related central nervous system (CNS) symptoms which were 10.4%, whereas all psychiatric and nervous system disorders in this survey were low at 2.01% (26 cases) \[[@pone.0210384.ref019]\]. As for neoplasms, either benign or malignant, Kaposi's sarcoma could be considered a disease-specific complication, but the proportion of all remaining malignancies was as low as 0.08%. For long-term safety, no specific tendency was observed in the overall ADR risk by raltegravir treatment period, but the risk of metabolism and nutrition disorders increased as the raltegravir treatment period lengthened. However, nearly 40% of the patients were 45 years of age or older at the initiation of raltegravir and many patients have comorbidities including diabetes mellitus or hyperlipidaemia, therefore it cannot be concluded that the trend was caused by long-term use of raltegravir. Although the risk of malignancies in patients treated with raltegravir should continue to be monitored, the \<1% risk of most reported ADRs in this long-term safety assessment of a large Japanese cohort with over 1,000 patients suggests the general tolerability of raltegravir.

The effectiveness analysis was conducted on data from a total of 1,178 patients. The median HIV-1 RNA viral loads in treatment-naïve patients decreased rapidly after one month of raltegravir treatment and were identical in both treatment-naïve and treatment-experienced patients after 3 months of raltegravir treatment. Although decreasing numbers on raltegravir treatment as time goes on, using this as denominator, the proportion of patients with \<50 copies/mL of HIV-1 RNA remained at 92.00% (23/25 cases, 95%CI: 73.97--99.02) in patients treated for 7 years, which is higher than or at a similar level as the corresponding proportions reported by previous clinical trials conducted overseas for a maximum of 5 years \[[@pone.0210384.ref001]--[@pone.0210384.ref008]\], suggesting a long-term virologic suppression by raltegravir treatment in Japanese patients.

Similarly, the median CD4^+^ cell counts in treatment-naïve patients were initially lower than those in treatment-experienced patients, but they rapidly increased to 346 cells/μL after 3 months of raltegravir treatment and were maintained at \>500 cells/μL after 3 years of raltegravir in treatment-naïve patients and after 4 years in treatment-experienced patients. Previous studies reported that the changes in CD4^+^ cell counts from baseline were 189 cells/μL, 240 cells/μL, and 374 cells/μL in treatment-naïve patients (STARTMRK study) and 109 cells/μL, 123 cells/μL, and 293 cells/μL in patients with triple-class drug resistance in whom previous ART had failed (BENCHMRK-1 and -2 study) after approximately 1 year, 2 years, and 5 years of raltegravir administration, respectively \[[@pone.0210384.ref003]--[@pone.0210384.ref008]\]. In the present survey, we found an increase by 218 cells/μL, 278 cells/μL, and 325 cells/μL in treatment-naïve patients and by 41 cells/μL, 72 cells/μL, and 127.5 cells/μL in treatment-experienced patients after 1-, 2-, and 5-year treatment with raltegravir, respectively; this result may indicate an equivalent or better improvement regarding CD4^+^ cell counts resulted from virological suppression in raltegravir-treated Japanese patients. The observed improvement in the immunologic response even for treatment-experienced patients implies that an improvement for patients is likely after changing their ART regimen to include raltegravir.

There are several limitations to the present study. First, our results may be specific to particular groups of patients with HIV infection. The included patients in this study were registered at designated institutions, and, although in principle all patients receiving raltegravir were registered, each enrolment decision was made by contractor investigators. Therefore, a selection bias is inevitable. Second, the effectiveness results in this study cannot be purely attributed to raltegravir because antiretrovirals are commonly used in combinations. The present results support the effectiveness of raltegravir, but they must be interpreted with care. Third, as this data was drawn from HRD cooperative survey conducted by all companies having an HIV drug approved in Japan, we can only extract data of patients still on treatment with raltegravir at the time of the annual report. If patients collected as raltegravir data and switched for viral loads ≥50 copies/mL judged from collected effectiveness data, these patients were counted as failure. However, after they have switched to another ART regimen, we might not have been able to follow them any longer in this study. Therefore, a selection bias for over estimating effectiveness is inevitable. Fourth, as we had no control group for comparison, the safety and effectiveness results for raltegravir cannot be compared with those in HIV-infected patients who received no or other antiretroviral treatments. Last, data on patients who were treated with raltegravir for longer than 7 years were scarce, which may have limited the precision of those results.

In conclusion, long-term treatment with raltegravir is well-tolerated and effective regarding viral suppression, as measured by HIV-1 RNA levels and CD4^+^ cell counts, in Japanese HIV patients. Such benefits can be expected not only for patients who are about to start antiretroviral therapy but also for patients who switch antiretroviral regimens to one including raltegravir.
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###### Adverse drug reactions and laboratory abnormalities reported in patients (n = 1,293).
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Click here for additional data file.

###### Changes in the median HIV-1 RNA viral loads of treatment-naïve patients and treatment-experienced patients.

Detection threshold of HIV-1 RNA viral loads were treated as 39 until 2011, and 19 since 2012.
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Click here for additional data file.

###### Proportion of patients with \<50 copies/mL of HIV-1 RNA in patients treated with raltegravir.

^a^Case counts include blip cases (\<50 copies/mL with transient increases up to 1000 copies/mL).
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Click here for additional data file.

###### Change in median CD4+ cell counts of treatment-naïve patients and treatment-experienced patients.
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Click here for additional data file.
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